PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/70, 9/12 — A1

(11) International Publication Number: WO 95/30409

(43) International Publication Date: 16 November 1995 (16.11.95)

(21) International Application Number: PCT/CA95/00260

(22) International Filing Date: 2 May 1995 (02.05.95)

(30) Priority Data:
238,409 5 May 1994 (05.05.94) US

(60) Parent Application or Grant
(63) Related by Continuation
US 238,409 (CIP)
Filed on 5 May 1994 (05.05.94)

(71) Applicant *(for all designated States except US)*: MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: WINTERS, Conrad [GB/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). CLAS, Sophie-Dorothee [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). KWONG, Elizabeth [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). MEISNER, Dale [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). VADAS, Elizabeth, B. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).

(74) Agent: MURPHY, Kevin, P.; Swabey, Ogilvy, Renault, 1981 McGill College Avenue, Suite 1600, Montreal, Quebec H3A 2Y3 (CA).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TOPICAL POLYMERIC DRUG DELIVERY SYSTEM

(57) Abstract

A topical polymeric drug delivery system for the delivery of drugs to the skin for either topical or systemic effect is described. The system involves the use of a propellant-free airless pump for the delivery.

TITLE OF THE INVENTION

TOPICAL POLYMERIC DRUG DELIVERY SYSTEM

This application is a continuation-in-part of copending application Serial No. 08/238,409 filed May 5, 1994.

BACKGROUND OF THE INVENTION

The present invention is directed to a topical polymeric delivery system for the administration of certain drugs over an extended period of time via a non-propellant aerosol pump device.

Sustained release devices for controlled topical delivery of drugs is a highly useful method of supplying medication when it is beneficial to administer medication continuously. The idea of aerosol delivery of a thin film for direct spraying on a wound has been described in an article by Fujita et al., "Pharmaceutical Research" 9, (1992). However, the method described involves a CFC containing aerosol propellant.

Some of the advantages of this system over known transdermal delivery systems include:

1) Ease of application;
2) Ease of removal since the film is water soluble;
3) Freedom from adhesives;
4) Freedom from the use of a rate controlling membrane;
5) High patient acceptability as the film is practically invisible; and
6) The use of a propellant-free aerosol which is environmentally friendly.

SUMMARY OF THE INVENTION

According to the present invention it has been discovered that certain drugs can be delivered via a propellant-free aerosol as a component of a polymeric system for prolonged administration compared to conventional formulations. In particular, the compound indomethacin and certain cyclooxygenase II inhibitors such as 3-[3,4-

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/70, 9/12 — A1

(11) International Publication Number: **WO 95/30409**

(43) International Publication Date: 16 November 1995 (16.11.95)

(21) International Application Number: PCT/CA95/00260

(22) International Filing Date: 2 May 1995 (02.05.95)

(30) Priority Data:
238,409 5 May 1994 (05.05.94) US

(60) Parent Application or Grant
(63) Related by Continuation
US 238,409 (CIP)
Filed on 5 May 1994 (05.05.94)

(71) Applicant *(for all designated States except US)*: MERCK FROSST CANADA INC. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: WINTERS, Conrad [GB/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). CLAS, Sophie-Dorothee [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). KWONG, Elizabeth [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). MEISNER, Dale [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA). VADAS, Elizabeth, B. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Quebec H9H 3L1 (CA).

(74) Agent: MURPHY, Kevin, P.; Swabey, Ogilvy, Renault, 1981 McGill College Avenue, Suite 1600, Montreal, Quebec H3A 2Y3 (CA).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TOPICAL POLYMERIC DRUG DELIVERY SYSTEM

(57) Abstract

A topical polymeric drug delivery system for the delivery of drugs to the skin for either topical or systemic effect is described. The system involves the use of a propellant-free airless pump for the delivery.

TITLE OF THE INVENTION

TOPICAL POLYMERIC DRUG DELIVERY SYSTEM

This application is a continuation-in-part of copending application Serial No. 08/238,409 filed May 5, 1994.

BACKGROUND OF THE INVENTION

The present invention is directed to a topical polymeric delivery system for the administration of certain drugs over an extended period of time via a non-propellant aerosol pump device.

Sustained release devices for controlled topical delivery of drugs is a highly useful method of supplying medication when it is beneficial to administer medication continuously. The idea of aerosol delivery of a thin film for direct spraying on a wound has been described in an article by Fujita et al., "Pharmaceutical Research" 9, (1992). However, the method described involves a CFC containing aerosol propellant.

Some of the advantages of this system over known transdermal delivery systems include:

1) Ease of application;
2) Ease of removal since the film is water soluble;
3) Freedom from adhesives;
4) Freedom from the use of a rate controlling membrane;
5) High patient acceptability as the film is practically invisible; and
6) The use of a propellant-free aerosol which is environmentally friendly.

SUMMARY OF THE INVENTION

According to the present invention it has been discovered that certain drugs can be delivered via a propellant-free aerosol as a component of a polymeric system for prolonged administration compared to conventional formulations. In particular, the compound indomethacin and certain cyclooxygenase II inhibitors such as 3-[3,4-

5. Progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, 19-nor-progesterone, norethindrone, medroxyprogesterone and 17 β-hydroxy-progesterone;
6. Humoral agents such as the prostaglandins, for example, PGE_1, PGE_2 and PFG_2;
7. Antipyretics analgesics such as aspirin, sodium salicylate, salicylamide and diflunisal;
8. Antispasmodics such as atropine, methantheline, papaverine and methscopolamine bromide;
9. Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine and chlorophenazine;
10. Non steroidal anti-inflammatory agents such as indomethacin and sulindac; and
11. Cyclooxygenase II inhibitors such as those disclosed in U.S. Patent No. 5,409,944 issued April 25, 1995 and those disclosed in copending applications 08/147,804 filed November 4, 1993; 08/179,467 filed January 10, 1994; 08/330,172 filed October 27, 1994; 08/361,268 filed December 21, 1994 and 08/371,179 filed January 11, 1995.

Other drugs having the same or different physiological activity as those recited above can be employed in drug-delivery devices within the scope of the present invention.

This system is particularly useful with drugs such as indomethacin which can cause severe upper gastrointestinal irritation and nausea when administered by conventional means.

The system involves the use of film forming polymers which are soluble and rapidly form a thin film upon application via a hydrocarbon propellant-free system. The film formed allows vapor penetration and can be considered breathable. The choice of a chloro-fluoro-carbon (CFC) free preparation was essential due to the potentially environmentally damaging characteristics of CFC propellants. With the use of a hydrocarbon propellant-free system, it was also essential that the solvent employed be volatile enough to allow

EXAMPLE I

Film Formation

PHEMA was dissolved in a Tween/ethanol solution which had been warmed to 50°C. Indomethacin free acid was added to the solution and when fully dissolved the resultant solution was poured into a glass petri dish. The petri dish was covered with an inverted funnel and the solution was left to evaporate to dryness at room temperature. The films were placed in a vacuum oven for 16 hours at 37°C to ensure that the moisture level in all films was comparable. Moisture levels were determined to be less than 3%, in all films, by thermogravimetric analysis. As a percentage of the total solid contents of the film, indomethacin was present in quantities ranging from 9 to 14%, and Tween 20 from 14 to 45%. In films containing HPBCD, quantities were used which gave molar ratios of 1:1, 1:2 and 1:3, indomethacin:HPBCD.

EXAMPLE II

In Vitro Dissolution Testing of Films with Indomethacin

Films were cut to the appropriate size to fit an Enhancer cell (Vankel Industries, USA) and were weighed before testing. The film was covered with a Durapore membrane filter (Millipore, USA) to provide additional mechanical support. Dissolution testing, using the USP paddle method (100 r.p.m.), was carried out in phosphate buffer (pH 7.2) at 37°C. Samples were taken over an eight hour period and indomethacin concentration was quantitated by HPLC.

HPLC Conditions

A Beckman Ultrasphere 5μ C-18 (4.6 x 250 mm) column was used at 40°C with a mobile phase of 35% aqueous (3% acetic acid in distilled water) and 65% organic (15% acetonitrile and 85% methanol) phases. Flow rate was 1 ml/min. When analyzing Indomethacin

5. Progestational agents such as progesterone, megestrol, melengestrol, chlormadinone, ethisterone, norethynodrel, 19-nor-progesterone, norethindrone, medroxyprogesterone and 17 β-hydroxy-progesterone;
6. Humoral agents such as the prostaglandins, for example, PGE_1, PGE_2 and PFG_2;
7. Antipyretics analgesics such as aspirin, sodium salicylate, salicylamide and diflunisal;
8. Antispasmodics such as atropine, methantheline, papaverine and methscopolamine bromide;
9. Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine and chlorophenazine;
10. Non steroidal anti-inflammatory agents such as indomethacin and sulindac; and
11. Cyclooxygenase II inhibitors such as those disclosed in U.S. Patent No. 5,409,944 issued April 25, 1995 and those disclosed in copending applications 08/147,804 filed November 4, 1993; 08/179,467 filed January 10, 1994; 08/330,172 filed October 27, 1994; 08/361,268 filed December 21, 1994 and 08/371,179 filed January 11, 1995.

Other drugs having the same or different physiological activity as those recited above can be employed in drug-delivery devices within the scope of the present invention.

This system is particularly useful with drugs such as indomethacin which can cause severe upper gastrointestinal irritation and nausea when administered by conventional means.

The system involves the use of film forming polymers which are soluble and rapidly form a thin film upon application via a hydrocarbon propellant-free system. The film formed allows vapor penetration and can be considered breathable. The choice of a chloro-fluoro-carbon (CFC) free preparation was essential due to the potentially environmentally damaging characteristics of CFC propellants. With the use of a hydrocarbon propellant-free system, it was also essential that the solvent employed be volatile enough to allow

EXAMPLE I

Film Formation

PHEMA was dissolved in a Tween/ethanol solution which had been warmed to 50°C. Indomethacin free acid was added to the solution and when fully dissolved the resultant solution was poured into a glass petri dish. The petri dish was covered with an inverted funnel and the solution was left to evaporate to dryness at room temperature. The films were placed in a vacuum oven for 16 hours at 37°C to ensure that the moisture level in all films was comparable. Moisture levels were determined to be less than 3%, in all films, by thermogravimetric analysis. As a percentage of the total solid contents of the film, indomethacin was present in quantities ranging from 9 to 14%, and Tween 20 from 14 to 45%. In films containing HPBCD, quantities were used which gave molar ratios of 1:1, 1:2 and 1:3, indomethacin:HPBCD.

EXAMPLE II

In Vitro Dissolution Testing of Films with Indomethacin

Films were cut to the appropriate size to fit an Enhancer cell (Vankel Industries, USA) and were weighed before testing. The film was covered with a Durapore membrane filter (Millipore, USA) to provide additional mechanical support. Dissolution testing, using the USP paddle method (100 r.p.m.), was carried out in phosphate buffer (pH 7.2) at 37°C. Samples were taken over an eight hour period and indomethacin concentration was quantitated by HPLC.

HPLC Conditions

A Beckman Ultrasphere 5µ C-18 (4.6 x 250 mm) column was used at 40°C with a mobile phase of 35% aqueous (3% acetic acid in distilled water) and 65% organic (15% acetonitrile and 85% methanol) phases. Flow rate was 1 ml/min. When analyzing Indomethacin

to define the area of the paw to be monitored. The paw volume was measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water displacement. The animals were then injected subplantarly with 50 µl of a 1% carrageenan solution in saline (FMC Corp., Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e., 500 µg carrageenan per paw). Three hours later, the paw volume was measured and the increases in the paw volume were calculated. A five hour plasma sample was also taken to correlate the plasma levels with % paw edema inhibition. The animals were euthanized by CO_2 asphyxiation. Paw edema data were compared with the vehicle control group and percent inhibition calculated taking the values in the control group as 100%. The topical formulation was given at different doses to the animals and was also compared to an orally administered dose of indomethacin and a commercially available topical gel formulation of indomethacin. Representative results are shown in Table 1.

WHAT IS CLAIMED IS:

1. A topical polymeric delivery system suitable for administering a drug soluble in hydroalcoholic solutions which comprises:

(a) a film forming polymer;
(b) a plasticizing agent;
(c) a crystallization inhibitor/stabilizer;
(d) a penetration enhancer;
(e) an alcoholic or hydroalcoholic solution; and
(f) a suitable drug.

2. The system according to Claim 1 wherein the drug is optionally administered via a propellant-free aerosol pump.

3. The system according to Claim 1 wherein the film forming polymer is selected from the group consisting of methacrylates, celluloses and siloxanes and co-polymers of methacrylates, celluloses and siloxanes.

4. The system according to Claim 3 wherein the film forming polymer is a methacrylate.

5. The system according to Claim 4 wherein the methacrylate is poly(2-hydroxy ethyl methacrylate).

6. The system according to Claim 1 wherein the plasticizing agent is selected from Tween, low molecular weight polyglycols, glycerin or Labrasols.

7. The system according to Claim 6 wherein the plasticizing agent is Tween 20.

to define the area of the paw to be monitored. The paw volume was measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water displacement. The animals were then injected subplantarly with 50 µl of a 1% carrageenan solution in saline (FMC Corp., Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e., 500 µg carrageenan per paw). Three hours later, the paw volume was measured and the increases in the paw volume were calculated. A five hour plasma sample was also taken to correlate the plasma levels with % paw edema inhibition. The animals were euthanized by CO_2 asphyxiation. Paw edema data were compared with the vehicle control group and percent inhibition calculated taking the values in the control group as 100%. The topical formulation was given at different doses to the animals and was also compared to an orally administered dose of indomethacin and a commercially available topical gel formulation of indomethacin. Representative results are shown in Table 1.

WHAT IS CLAIMED IS:

1. A topical polymeric delivery system suitable for administering a drug soluble in hydroalcoholic solutions which comprises:

(a) a film forming polymer;
(b) a plasticizing agent;
(c) a crystallization inhibitor/stabilizer;
(d) a penetration enhancer;
(e) an alcoholic or hydroalcoholic solution; and
(f) a suitable drug.

2. The system according to Claim 1 wherein the drug is optionally administered via a propellant-free aerosol pump.

3. The system according to Claim 1 wherein the film forming polymer is selected from the group consisting of methacrylates, celluloses and siloxanes and co-polymers of methacrylates, celluloses and siloxanes.

4. The system according to Claim 3 wherein the film forming polymer is a methacrylate.

5. The system according to Claim 4 wherein the methacrylate is poly(2-hydroxy ethyl methacrylate).

6. The system according to Claim 1 wherein the plasticizing agent is selected from Tween, low molecular weight polyglycols, glycerin or Labrasols.

7. The system according to Claim 6 wherein the plasticizing agent is Tween 20.

h) Antispasmodics such as atropine, methantheline, papaverine, and methscopolamine bromide;

i) Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine, and chlorophenazine;

j) Non steroidal anti-inflammatory agents such as indomethacin, and sulindac; and

k) Cyclooxygenase II inhibitors such as 3-[3,4-difluorophenyl]-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone.

10. The system according to Claim 9 wherein the drug is selected from the group consisting of non-steroidal and steroidal anti-inflammatory agents, antihistamines and cyclooxygenase II inhibitors.

11. A method for the topical or systemic delivery of a therapeutic dose of a drug selected from the group consisting of

a) Protein drugs such as insulin;

b) Anti-infectives, such as antibiotics, including penicillin, tetracycline, chlorotetracycline bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole, cefoxitin; anti-virals including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate;

c) Steroidal anti-inflammatory agents such as hydrocortisone, cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 21-phosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 21-phosphate, and prednisolone acetate;

d) Estrogens such as estrone, 17 β-estradiol, ethinyl estradiol, and diethyl stilbesterol;

hydroxypropyl beta-cyclodextrin, the alcoholic solution is absolute ethanol and the drug is indomethacin.

15. A method for the topical or systemic delivery of a therapeutic dose of 3-[3,4-difluorophenyl]-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone which comprises employing the system of Claim 1.

16. A topical polymeric delivery system according to Claim 1 wherein the polymer is poly(2-hydroxy ethyl methacrylate), the plasticizing agent is Tween 20, the crystallization inhibitor is hydroxypropyl beta-cyclodextrin, the alcoholic solution is absolute ethanol and the drug is 3-[3,4-difluorophenyl]-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone.

17. A topical polymeric delivery system for administering a drug which comprises:

(a) a film forming polymer;
(b) a plasticizing agent;
(c) a solvent effective for film formation of said polymer, and
(d) at least one of:
  (i) a crystallization inhibitor/stabilizer; and
  (ii) a penetration enhancer.

18. A system of Claim 18 for use in topical or systemic delivery of a drug soluble in said solvent.

h) Antispasmodics such as atropine, methantheline, papaverine, and methscopolamine bromide;

i) Antihistamines such as diphenhydramine, dimenhydrinate, tripelennamine, perphenazine, and chlorophenazine;

j) Non steroidal anti-inflammatory agents such as indomethacin, and sulindac; and

k) Cyclooxygenase II inhibitors such as 3-[3,4-difluorophenyl]-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone.

10. The system according to Claim 9 wherein the drug is selected from the group consisting of non-steroidal and steroidal anti-inflammatory agents, antihistamines and cyclooxygenase II inhibitors.

11. A method for the topical or systemic delivery of a therapeutic dose of a drug selected from the group consisting of

a) Protein drugs such as insulin;

b) Anti-infectives, such as antibiotics, including penicillin, tetracycline, chlorotetracycline bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethizole, sulfamethazine, sulfadiazine, sulfamerazine, and sulfisoxazole, cefoxitin; anti-virals including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate;

c) Steroidal anti-inflammatory agents such as hydrocortisone, cortisone, hydrocortisone acetate, dexamethasone, dexamethasone 21-phosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 21-phosphate, and prednisolone acetate;

d) Estrogens such as estrone, 17 β-estradiol, ethinyl estradiol, and diethyl stilbesterol;

hydroxypropyl beta-cyclodextrin, the alcoholic solution is absolute ethanol and the drug is indomethacin.

15. A method for the topical or systemic delivery of a therapeutic dose of 3-[3,4-difluorophenyl]-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone which comprises employing the system of Claim 1.

16. A topical polymeric delivery system according to Claim 1 wherein the polymer is poly(2-hydroxy ethyl methacrylate), the plasticizing agent is Tween 20, the crystallization inhibitor is hydroxypropyl beta-cyclodextrin, the alcoholic solution is absolute ethanol and the drug is 3-[3,4-difluorophenyl]-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone.

17. A topical polymeric delivery system for administering a drug which comprises:

(a) a film forming polymer;
(b) a plasticizing agent;
(c) a solvent effective for film formation of said polymer, and
(d) at least one of:
  (i) a crystallization inhibitor/stabilizer; and
  (ii) a penetration enhancer.

18. A system of Claim 18 for use in topical or systemic delivery of a drug soluble in said solvent.

INTERNATIONAL SEARCH REPORT

National Application No
PCT/CA 95/00260

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 319 964 (SHIONOGI SEIYAKU KK) 14 June 1989 see page 2; claims 1,4,6; examples 2-4	1,3,4,6, 9,11,17, 18
X	EP,A,0 521 455 (TAKEDA CHEMICAL INDUSTRIES LTD.) 7 January 1993	17,18
A	see page 3-4; claims 1,7,8	1-4,6, 9-14
A	JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 63, no. 9, 1974 pages 1376-1379, LUONGO, SCIARRA, WARD 'IN VIVO METHOD FOR DETERMINING EFFECTIVENESS OF SPRAY-ON BANDAGES CONTAINING ANTI-INFECTIVES' see page 1376, right column	1-3,9, 11,17,18
A	EP,A,0 542 356 (MERCK FROSST CANADA INC.) 19 May 1993 see page 2-3; claims 5-8,11,12	8-16
A	FR,A,2 344 291 (MINNESOTA MINING AND MAFUFACTURING COMPANY) 14 October 1977 see page 4 - page 8, paragraph 2; claims 1,3; tables 2-5	3,4,6,7, 9,11,17, 18
A	US,A,5 262 087 (KOSE CORPORATION) 16 November 1993 see column 3-7	1,3

INTERNATIONAL SEARCH REPORT

National Application No
PCT/CA 95/00260

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 319 964 (SHIONOGI SEIYAKU KK) 14 June 1989 see page 2; claims 1,4,6; examples 2-4	1,3,4,6, 9,11,17, 18
X	EP,A,0 521 455 (TAKEDA CHEMICAL INDUSTRIES LTD.) 7 January 1993	17,18
A	see page 3-4; claims 1,7,8	1-4,6, 9-14
A	JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 63, no. 9, 1974 pages 1376-1379, LUONGO, SCIARRA, WARD 'IN VIVO METHOD FOR DETERMINING EFFECTIVENESS OF SPRAY-ON BANDAGES CONTAINING ANTI-INFECTIVES' see page 1376, right column	1-3,9, 11,17,18
A	EP,A,0 542 356 (MERCK FROSST CANADA INC.) 19 May 1993 see page 2-3; claims 5-8,11,12	8-16
A	FR,A,2 344 291 (MINNESOTA MINING AND MAFUFACTURING COMPANY) 14 October 1977 see page 4 - page 8, paragraph 2; claims 1,3; tables 2-5	3,4,6,7, 9,11,17, 18
A	US,A,5 262 087 (KOSE CORPORATION) 16 November 1993 see column 3-7	1,3